Tonix Pharmaceuticals reported $6.9 million in net product revenue for Q1 2026, driven by the launch of TONMYA, the first new fibromyalgia drug in 15 years. Since its November 2025 launch, TONMYA has been prescribed by over 2,700 healthcare providers to more than 5,600 patients, with growing prescription fills and payer coverage expanding to 35 million commercial lives. The company is advancing its pipeline, including a planned Phase 2 adaptive field study for TNX-4800, a monoclonal antibody for Lyme disease prevention, expected to start in early 2027 pending FDA approval. Tonix also plans Phase 2 studies for TONMYA in major depressive disorder and continues development across CNS, infectious disease, immunology, and rare diseases.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
